Jupiter Neurosciences Inc. (NASDAQ: JUNS) announced it entered into a securities purchase agreement to sell 7,142,858 shares of common stock in a registered direct offering generating approximately $2.0 million in gross proceeds.

The clinical-stage biopharmaceutical company focuses on central nervous system disorders and neuroinflammation. D. Boral Capital LLC serves as the exclusive placement agent for the offering.

The closing is expected to occur on or about May 21, 2026, subject to customary closing conditions. The shares are being offered under an effective shelf registration statement on Form S-3, which the Securities and Exchange Commission declared effective on April 24, 2026.

Jupiter Neurosciences is advancing a therapeutic pipeline targeting central nervous system disorders. The company's lead program, JOTROL, is a resveratrol formulation currently in a Phase IIa clinical trial for Parkinson's disease. The company also commercializes Nugevia, a consumer longevity supplement.

A prospectus supplement describing the terms of the registered direct offering will be filed with the SEC and will be available on the SEC's website once filed.